Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer

Table 1

Clinicopathologic factors affecting progression-free and overall survivals in all 360 patients with advanced-stage ovarian cancer.

Characteristics	Univariate			Multivariate
	HR	95% CI	𝑃 value	Adjusted HR	95% CI	𝑃 value
Progression-free survival
≥53 years	1.04	0.82–1.32	0.74	—	—	—
Stage IV disease	1.27	0.95–1.69	0.11	—	—	—
Grade 3 disease	1.11	0.80–1.53	0.53	—	—	—
Nonserous histology	1.26	0.95–1.67	0.11	—	—	—
No neoadjuvant chemotherapy	1.62	1.19–2.20	<0.01	1.84	1.18–2.87	<0.01
≤6 cycles of adjuvant chemotherapy	1.03	0.81–1.32	0.81	—	—	—
Suboptimal debulking surgery	1.54	1.21–1.96	<0.01	1.71	1.22–2.39	<0.01
Underweight after treatment	1.25	0.80–1.93	0.33	—	—	—
Overall survival
≥53 years	1.12	0.79–1.58	0.52	—	—	—
Stage IV disease	1.21	0.80–1.84	0.36	—	—	—
Grade 3 disease	1.21	0.75–1.93	0.44	—	—	—
Nonserous histology	1.58	1.07–2.33	0.02	—	—	—
No neoadjuvant chemotherapy	1.65	1.08–2.54	0.02	1.88	1.28–2.77	<0.01
≤6 cycles of adjuvant chemotherapy	1.16	0.82–1.64	0.42	—	—	—
Suboptimal debulking surgery	1.49	1.05–2.11	0.03	1.67	1.23–2.28	<0.01
Underweight after treatment	2.01	1.13–3.58	0.02	2.29	1.08–4.85	0.03